Systematic Multiplatform Discovery of Methylation Markers Enables Non‐Invasive Early Detection of Endometrial Cancer
Cancer Science · 2026-05 · 117 (5) · 1412-1421
DOI: 10.1111/cas.70346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 07.03.2026. Verfasst von Yan Cai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gynecologic Oncology, Peking University Ca…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, DNA Methylation, Early Detection of Cancer, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital..
Abstract (Originalsprache)
Endometrial cancer, the most common gynecological malignancy with an annual increase of 1%–3%, lacks suitable noninvasive diagnostic tools, as current methods like hysteroscopy and biopsy are invasive and impractical for routine screening. We conducted a comprehensive, multilayered marker discovery workflow integrating whole‐genome bisulfite sequencing and targeted methylation panels in tumor and control tissues, then prioritized and optimized candidates for detection in cervical exfoliated cells. Using a two‐stage design, we built and tested a quantitative methylation–specific PCR (qMSP) model in ThinPrep Cytology Test (TCT) samples, with 148 samples for discovery/model construction and an independent cohort of 80 TCT samples for validation. We identified a three‐gene methylation panel—ZNF626, GRIA4, and SPDYA—that demonstrated high accuracy for early endometrial cancer detection from cervical cytology. In the validation cohort, the model showed strong performance across menopausal subgroups: in premenopausal women, sensitivity was 90.91% and specificity for benign endometrial disease was 92.59%; in postmenopausal women, sensitivity and specificity were 96.55% and 84.62%, respectively. Notably, the approach achieved a 92.86% detection rate for stage I endometrial cancer. These results support a robust, noninvasive diagnostic strategy that leverages simple cervical cytology sampling to enable early detection, facilitate clinical decision‐making, and potentially improve outcomes for patients at risk of endometrial cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gynecologic Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- BioChain (Beijing) Science & Technology Inc., Beijing, China.
ORCID-Profile: Jie Zhao
Förderung
- Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital.
Zitieren
APA
Cai, Y., Chen, S., Wu, Z., Guan, J., Zhao, J., Ye, J., Du, B., Han, X., Shu, T., Zhou, G., & Zheng, H. (2026). Systematic Multiplatform Discovery of Methylation Markers Enables Non‐Invasive Early Detection of Endometrial Cancer. Cancer Science, 117(5), 1412-1421. https://doi.org/10.1111/cas.70346
Vancouver
Cai Y, Chen S, Wu Z, Guan J, Zhao J, Ye J, et al. Systematic Multiplatform Discovery of Methylation Markers Enables Non‐Invasive Early Detection of Endometrial Cancer. Cancer Science. 2026;117(5):1412-1421. doi:10.1111/cas.70346
BibTeX
@article{Cai2026,
author = {Cai, Yan and Chen, Shuchao and Wu, Zhen and Guan, Jinxia and Zhao, Jie and Ye, Jianwei and Du, Baochen and Han, Xiaoliang and Shu, Tong and Zhou, Guangpeng and Zheng, Hong},
title = {Systematic Multiplatform Discovery of Methylation Markers Enables Non‐Invasive Early Detection of Endometrial Cancer},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {5},
pages = {1412--1421},
doi = {10.1111/cas.70346}
}
EUVIMED